Mutual of America Capital Management LLC Sells 8,657 Shares of Gilead Sciences, Inc. $GILD

Mutual of America Capital Management LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 155,631 shares of the biopharmaceutical company’s stock after selling 8,657 shares during the period. Mutual of America Capital Management LLC’s holdings in Gilead Sciences were worth $17,275,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GILD. Vanguard Group Inc. grew its position in shares of Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after acquiring an additional 727,515 shares in the last quarter. Norges Bank purchased a new stake in Gilead Sciences during the second quarter valued at about $2,150,268,000. Invesco Ltd. raised its holdings in Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares during the last quarter. Finally, Amundi grew its stake in shares of Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after purchasing an additional 1,614,355 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. This represents a 1.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the sale, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. The trade was a 67.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 141,757 shares of company stock valued at $17,569,112. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 3.7%

NASDAQ GILD opened at $135.93 on Monday. Gilead Sciences, Inc. has a one year low of $92.26 and a one year high of $136.30. The company has a market capitalization of $168.65 billion, a P/E ratio of 21.07, a P/E/G ratio of 0.71 and a beta of 0.33. The stock has a 50 day moving average price of $123.98 and a 200-day moving average price of $118.71. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the previous year, the firm posted $2.02 EPS. The business’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio is 48.99%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Scotiabank began coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target for the company. BMO Capital Markets reissued an “outperform” rating on shares of Gilead Sciences in a report on Tuesday, January 13th. Wells Fargo & Company raised their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Argus boosted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Finally, Sanford C. Bernstein set a $135.00 price objective on shares of Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.